Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories




 

Dr Reddy’s CEO Sees Strength Through Diversity

With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.

Strategy Generic Drugs

Interviews

Interviews

Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That

Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.

Biosimilars Manufacturing

Humira In 2023: The $17bn Biosimilar Opportunity

The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?

Biosimilars United States Market Intelligence
 

Commercial Explore this Topic

Set Alert for Commercial

Dr Reddy’s CEO Sees Strength Through Diversity

With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.

Strategy Generic Drugs

Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway

Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.

Value-Added Medicines Clinical Trials

Sun Forwards Specialty Strategy With $576m Concert Acquisition

Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.

Deals M & A

Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That

Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.

Biosimilars Manufacturing

Alvotech Taps Equity Financing As Venture Bears Fruit In Saudi Arabia

Alvotech has once again raised more than $100m in financing, the second time in a matter of months, via a private placement involving what it expects to be previously issued treasury shares held by one of its subsidiaries.

Financing Approvals

Sandoz Adds To Anti-Infectives With Astellas Mycamine Deal

Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.

Deals Strategy
See All

Policy & Regulation Explore this Topic

Set Alert for Policy and Regulation

BsUFA Research Roadmap Highlights Interchangeability And Reducing Trials

The FDA has published a “Research Roadmap” setting out in detail its areas of interest for the agency’s biosimilar regulatory science pilot program under BsUFA III.

Biologics Regulation

IGBA Struggles To Find Data On Global Drug Shortages For WHO

An IGBA research report suggests international health bodies lack an accurate picture of global essential medicines shortages due to issues with monitoring and recording.

International Supply Chain

Industry Warns Of New Post-Brexit ‘Cliff Edge’ For Medicines Supply To Northern Ireland

The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.

United Kingdom Europe

German Generic Reform To Relax Pediatric Pricing

Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.

Germany Generic Drugs

Biosimilars Forum Urges Equal Access For US Humira Rivals

With the US on the cusp of biosimilar competition to Humira, Julie Reed – executive director of the country’s Biosimilars Forum – has urged PBMs to bolster access by making all adalimumab biosimilars available as they launch throughout 2023.

Biosimilars United States

A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM

Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.

Leadership United States
See All

Generic Drugs Explore this Topic

Set Alert for Generic Drugs

Neuraxpharm’s New Belgian Division Advances European Expansion Strategy

Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established. 

Belgium Business Strategies

Dr Reddy’s CEO Sees Strength Through Diversity

With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.

Strategy Generic Drugs

Pfizer Adds Hundreds Of Drugs To Global Health Equity Initiative

Pfizer has added hundreds of off-patent products to the portfolio that it is offering on a not-for-profit basis to 45 lower-income countries under its global health equity initiative.

International Business Strategies
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

Samsung Bioepis Launches Ranibizumab In Korea

Samsung Bioepis has announced the launch of its SB11 ranibizumab biosimilar rival to Lucentis in Korea through partner Samil. The introduction – under the name Amelivu – comes after the product was launched as Byooviz in the US last year.

Biosimilars Launches

Fresenius Kabi: Adalimumab Customers Want Supply Guarantee, We Can Provide That

Following Fresenius Kabi’s approval in mid-December for the eighth and latest biosimilar Humira (adalimumab) product, the company’s senior vice president for biosimilars in the US spoke to Generics Bulletin about how it can stand out from the pack and why it is confident that it can succeed.

Biosimilars Manufacturing

Alvotech Taps Equity Financing As Venture Bears Fruit In Saudi Arabia

Alvotech has once again raised more than $100m in financing, the second time in a matter of months, via a private placement involving what it expects to be previously issued treasury shares held by one of its subsidiaries.

Financing Approvals
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway

Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.

Value-Added Medicines Clinical Trials

Viatris’ Once-Monthly Copaxone Filing Imminent, Botox ‘On Track’

Fresh from offloading almost all its interests in biosimilars to Biocon, Viatris continues to develop several follow-on products, which it hopes will add $1bn to the company’s top line by the end of the decade.

Value-Added Medicines United States

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

M & A Deals
See All
UsernamePublicRestriction

Register